18:11 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best...
19:50 , Aug 3, 2017 |  BC Innovations  |  Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
21:38 , Feb 23, 2017 |  BC Innovations  |  Tools & Techniques

Showdown: bacteria vs. virus

Drug developers are starting to revisit bacteriophages as a solution for two of the biggest questions in translational research: how to treat resistant bacterial infections, and how to manipulate the human microbiome. A spate of...
22:33 , Nov 3, 2016 |  BC Week In Review  |  Clinical News

AB-SA01: Ph I data

Top-line data from 9 patients with chronic rhinosinusitis associated with S. aureus infection in an open-label, Australian Phase I trial showed that 3x108 plaque-forming units (PFUs) of intranasal AB-SA01 dosed twice daily for 7 or...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

AB-SA01: Phase I data

Top-line data from a double-blind, placebo-controlled, U.S. Phase I trial in 12 healthy volunteers ages 18-60 showed that once-daily 1x10 8 and 1x10 9 plaque-forming units (PFUs)/mL of topical AB-SA01 applied to the forearm under...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

AB-SA01: Completed Phase I enrollment

AmpliPhi completed enrollment of about 12 healthy volunteers in a double-blind, U.S. Phase I trial to evaluate topical AB-SA01 applied once daily for 3 days. Subjects will receive 108 or 109 plaque-forming units (PFUs)/mL of...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

AB-SA01: Phase I started

AmpliPhi began a double-blind, U.S. Phase I trial to evaluate topical AB-SA01 applied once daily for 3 days in about 12 healthy volunteers. Subjects will receive 108 or 109 plaque-forming units (PFUs)/mL of AB-SA01 on...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

AB-SA01: Phase I started

AmpliPhi began an open-label, Australian Phase I trial to evaluate twice-daily intranasal AB-SA01 in about 9 patients who are refractory to standard therapy. Patients will receive 3x10 8 plaque-forming units (PFUs) of AB-SA01 for 7...
00:49 , Dec 17, 2013 |  BC Extra  |  Financial News

AmpliPhi raises $18 million

AmpliPhi Biosciences Corp. (OTCBB:APHB) raised $18 million through the sale of 72 million shares at $0.25 in a private placement. The price is a 44% discount to the company's close of $0.45 on Friday, the...